List of Peptide Therapies Companies in Michigan - 4

Diapin Therapeutics is a clinical-stage drug development company developing novel therapeutics for the treatment of cardiovascular and metabolic diseases. The company is focused on peptide-based therapies for diabetes and has announced groundbreaking results from the latest study of their compound DT-109, a novel oral tripeptide that inhibits NASH progression in non-human primates. Diapin Therapeutics is also known for its tripeptide Diapin, which effectively lowers blood glucose levels in male patients. The company has an option agreement with the University of Michigan to commercialize peptide-based therapies for cardiovascular and metabolic diseases.

ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to helping patients see the future. Our mission is to develop innovative therapeutics to protect and improve the vision of patients with a range of retinal disease and conditions. By advancing a breakthrough technology designed to prevent the death of key retinal cells caused by the activation of the natural Fas pathway, ONL is pioneering an entirely new approach to preserve sight. It is the first and only company focused on preventing Fas-mediated death of key retinal cells, which is a root cause of vision loss, a leading cause of blindness and an unaddressed medical need. ONL’s lead therapeutic candidate, ONL1204, is a first-in-class small peptide Fas inhibitor designed to protect retinal cells from both death and inflammatory signaling pathways. ONL1204 Ophthalmic Solution is being developed for the treatment of retinal detachment, an acute condition for which the company has been granted orphan drug designation by the FDA. In addition, the company is currently developing ONL1204 in geographic atrophy associated with age-related macular degeneration, glaucoma, and other acute and chronic indications.

Chemotherapy is the foundation of cancer treatment because it is so effective, but it is also the downfall of cancer treatment because it is so toxic. Patients can experience hair loss, nausea, fatigue, aching, or neuropathy and often find that the treatment seems worse than the disease. Imagine the impact a technology would have on cancer treatment if that technology maintains or even improves the efficacy of established chemotherapies without the harmful side effects. And that is what Peptinovo aims to do. Peptinovo Biopharma Inc. has invented and patented a targeted, drug-delivery platform: Peptide-Amphiphile Lipid Micelle (PALM) that reduces or eliminates chemotherapy-induced peripheral neuropathy (CIPN), one of the most serious side effects threatening treatment outcomes for world-leading chemotherapy drugs like paclitaxel. PALM delivers higher doses of proven drugs INTO tumors, keeping them AWAY from healthy tissues. Lives are extended and side effects are avoided. Peptinovo is developing its first platform, PNB-281, to eliminate the nerve damage caused by paclitaxel against many major cancers including breast, ovarian, lung, prostate, and pancreatic cancers. Nerve damage is the most serious side-effect threatening the ability to complete the cancer treatment. Peptinovo's technology can be used to treat many cancers and it can be used with many chemotherapy drugs.

Vestaron Crop Protection is an ag technology company dedicated to providing our customers with the powerful solutions they need to meet the growing challenges of modern agriculture. Founded in 2005 and headquartered in Durham, NC (USA), we are producing a pipeline of powerful insecticides with new modes of action based on peptides modified from the venom of spiders and other venomous animals. Naturally soft on pollinators, beneficials, and local biodiversity, our innovations have earned recognition from the Crop Science Awards and the EPA’s Green Chemistry Challenge. In 2024, we became the first agriculture and food company inducted into the Global CleanTech 100 Hall of Fame. Our first product, SPEAR® LEP, is proven on more than 650,000+ acres and continues to gain market share in North America. Recently, SPEAR LEP has been approved for Emergency Use Authorization in several EU countries as a desperately needed solution to help farmers combat the destructive impact of tomato leafminer (Tuta absoluta) infestations which cause substantial yield and economic losses for farmers across the Mediterranean region of Europe. In 2024 the Environmental Protection Agency (EPA) approved our second novel-acting insecticide, BASIN®. Vestaron Crop Protection: Unconventional, by nature.